Physician profile
Anthony Licata
NPI 1588643993
$5,530.12
in general payments reported to CMS, 2019-2025
33 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,256 · 2020: $211 · 2021: $454 · 2022: $337 · 2023: $508 · 2024: $405 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,979.26 | 2019-2025 | Diamondback Peripheral, Cardiomems, Aveir |
| Novartis Pharmaceuticals Corporation | $627.42 | 2019-2025 | |
| Amgen INC. | $251.34 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $245.72 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $234.24 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $229.58 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.26 | 2019-2025 | Jardiance |
| Pfizer INC. | $210.39 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $168.78 | 2019 | |
| Abiomed | $157.48 | 2022-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $147.28 | 2019-2025 | Camzyos |
| Lantheus Medical Imaging, INC. | $129.83 | 2021-2023 | Definity |
| Medtronic, INC. | $128.18 | 2023-2025 | Export Ap, Symplicity G3, Linq II |
| Astellas Pharma US INC | $119.91 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $96.57 | 2019-2025 | Uptravi, Opsumit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $71.39 | 2019-2020 | |
| United Therapeutics Corporation | $61.69 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $58.84 | 2019-2023 | Farxiga |
| Chiesi USA, INC. | $47.98 | 2022-2025 | Kengreal |
| Lundbeck LLC | $45.50 | 2019 | |
| Impulse Dynamics (USA) INC. | $44.78 | 2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $40.59 | 2019-2020 | |
| Scpharmaceuticals INC. | $34.23 | 2023 | |
| Daiichi Sankyo INC. | $32.24 | 2019 | |
| Akcea Therapeutics, INC. | $22.95 | 2020 | |
| Stryker Corporation | $22.31 | 2025 | Clottriever Bold Catheter |
| Edwards Lifesciences Corporation | $19.28 | 2025 | Sapien 3 Ultra Resilia |
| Lexicon Pharmaceuticals, INC. | $18.21 | 2023 | Inpefa |
| Philips North America LLC | $16.75 | 2023 | |
| Vifor Pharma, INC. | $13.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.77 | 2019 | |
| Portola Pharmaceuticals, LLC | $11.01 | 2019 | |
| Ge Healthcare | $9.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Licata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.